Literature DB >> 24805854

Intralymphatic cutaneous anaplastic large cell lymphoma/lymphomatoid papulosis: expanding the spectrum of CD30-positive lymphoproliferative disorders.

Mark A Samols1, Albert Su, Seong Ra, Mark A Cappel, Abner Louissant, Ryan A Knudson, Rhett P Ketterling, Jonathan Said, Scott Binder, Nancy Lee Harris, Andrew L Feldman, Jinah Kim, Youn H Kim, Dita Gratzinger.   

Abstract

Intravascular large B-cell lymphomas and EBV NK/T-cell lymphomas commonly follow an aggressive clinical course. We recently reported an entirely intravascular anaplastic large cell lymphoma (ALCL) in the skin with a surprisingly indolent clinical course; interestingly, this lymphoma involved the lymphatic rather than the blood vasculature. We hypothesized that intravascular skin-limited ALCL is distinct from aggressive systemic intravascular lymphomas in its intralymphatic localization and clinical course. We now describe 18 cases of cutaneous intravascular large cell lymphoproliferations from 4 institutions. All 12 intravascular large T-cell lesions were intralymphatic; the majority (9) were CD30 T-cell lymphoproliferative disorders (TLPDs), 5 further classified as intravascular ALK ALCL. One ALK ALCL and 2 benign microscopic intravascular T-cell proliferations were also intralymphatic. A single case of otherwise typical cutaneous follicle center lymphoma contained intralymphatic centroblasts. The clinical and pathologic characteristics of the CD30 TLPDs were similar to those of their extravascular counterparts, including extralymphatic dermal involvement in a subset, DUSP22-IRF4 translocations in half of tested ALK ALCLs, and associated mycosis fungoides in 1; most were skin-limited at baseline and remained so at relapse. All 5 cases of intravascular large B-cell lymphoma involved the blood vasculature and behaved in a clinically aggressive manner; the ALK ALCL, although intralymphatic, was systemic and clinically aggressive. We propose that cutaneous ALK ALCL and related CD30 ALK TLPDs involving the lymphatics are part of an expanding spectrum of CD30 TLPDs. The identification of intralymphatic as distinct from blood vascular localization may provide critical prognostic and therapeutic information.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24805854     DOI: 10.1097/PAS.0000000000000217

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  4 in total

1.  Benign Atypical Intralymphatic CD30+ T-Cell Proliferation: A Case Report and Literature Review.

Authors:  Nu Ri Jang; Min Kyoung Kim; Dong Hoon Shin; Mi Jin Gu
Journal:  Ann Dermatol       Date:  2019-01-02       Impact factor: 1.444

Review 2.  Intravascular Large B-Cell Lymphoma: A Review with a Focus on the Prognostic Value of Skin Involvement.

Authors:  Thomas Breakell; Heidi Waibel; Stefan Schliep; Barbara Ferstl; Michael Erdmann; Carola Berking; Markus V Heppt
Journal:  Curr Oncol       Date:  2022-04-19       Impact factor: 3.109

3.  A case report of aggressive course of CD30+ primary cutaneous anaplastic large cell lymphoma.

Authors:  Wen-Tian Lyu; Qi-Bin Song; Wang Qiong; Jing Liu; Ren Yong; Feng-Tao Yi; Dong-Liang Han
Journal:  Medicine (Baltimore)       Date:  2021-05-07       Impact factor: 1.889

4.  A case of exuberant cutaneous lymphomagenesis in the setting of chronic patch mycosis fungoides.

Authors:  Jason C Sluzevich; Han Tun; Demetria Strauch Jacks; Liuyan Jiang
Journal:  JAAD Case Rep       Date:  2015-01-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.